SEC Info - Grygiel Nancy A. - ‘3’ for 6/24/20 re: Amgen Inc.

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Grygiel Nancy A.

(Last)

(First)

(Middle)

ONE AMGEN CENTER DRIVE

(Street)

THOUSAND OAKS

91320

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
6/24/20

3. Issuer Name and Ticker or Trading Symbol
AMGEN INC [ AMGN ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
SVP & CCO

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	3,142 ⁽¹⁾ ⁽²⁾	D
Common Stock	88.786 ⁽³⁾	I	401(k) Plan

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Nqso (Right to Buy)	5/1/19 ⁽⁴⁾	5/1/27	Common Stock	4,139	162.6	D
Nqso (Right to Buy)	4/27/20 ⁽⁵⁾	4/27/28	Common Stock	3,470	177.46	D
Nqso (Right to Buy)	5/3/21 ⁽⁶⁾	5/3/29	Common Stock	3,948	177.31	D
Nqso (Right to Buy)	5/5/22 ⁽⁷⁾	5/5/30	Common Stock	3,542	236.36	D

Explanation of Responses:

(1) These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 748 RSUs which fully vest on 8/1/20; 159 RSUs which fully vest on 5/1/21; 302 RSUs which vest in two installments of 149 on 4/27/21 and 153 on 4/27/22; 452 RSUs which vest in two installments of 149 on 5/3/21 and 5/3/22 and one installment of 154 on 5/3/23; and 423 RSUs which vest in installments of 139 on 5/5/22, 140 on 5/5/23 and 144 on 5/5/24. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

(2) These shares include 142 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

(3) These are shares acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing.

(4) 2,731 of these non-qualified stock options have vested and are exercisable and 1,408 of these options will vest and become exercisable on 5/1/21.

(5) 1,145 of these non-qualified stock options have vested and are exercisable and the remaining options will vest and become exercisable in installments of 1,145 on 4/27/21 and 1,180 on 4/27/22.

(6) These non-qualified stock options will vest and become exercisable in three installments of 1,302 on 5/3/21, 1,303 on 5/3/22 and 1,343 on 5/3/23.

(7) These non-qualified stock options will vest and become exercisable in three installments of 1,168 on 5/5/22, 1,169 on 5/5/23 and 1,205 on 5/5/24.

	/s/ Andrea A. Robinson, Attorney-in-Fact for Ms. Grygiel	6/30/20
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Grygiel Nancy A. – ‘3’ for 6/24/20 re: Amgen Inc.

On: Wednesday, 7/1/20, at 8:00pm ET · For: 6/24/20 · Accession #: 1127602-20-20691 · File #: 1-37702

Initial Statement of Beneficial Ownership of Securities by an Insider — Form 3 — SEA’34
Filing Table of Contents

‘3’ — Initial Statement of Beneficial Ownership of Securities by an Insider — form3.xml/2.6

This ‘3’ Document is an XML Data File that may be rendered in various formats:

Grygiel Nancy A. – ‘3’ for 6/24/20 re: Amgen Inc.

On: Wednesday, 7/1/20, at 8:00pm ET · For: 6/24/20 · Accession #: 1127602-20-20691 · File #: 1-37702

Initial Statement of Beneficial Ownership of Securities by an Insider — Form 3 — SEA’34Filing Table of Contents

‘3’ — Initial Statement of Beneficial Ownership of Securities by an Insider — form3.xml/2.6

This ‘3’ Document is an XML Data File that may be rendered in various formats:

Initial Statement of Beneficial Ownership of Securities by an Insider — Form 3 — SEA’34
Filing Table of Contents